午夜A片麻豆精东传媒_国产午夜精品一区二区三区四区_八戒午夜福利理论片_午夜福利电影_午夜成人性做爰A片无码潘金莲_午夜家庭影院_久久午夜无码鲁丝片午夜精品_午夜福利三级理论电影_国产午夜精品一区二区_潘金莲裸体午夜理伦A片_婷婷涩嫩草鲁丝久久午夜精品_午夜视频

這(zhè)是(shì)描述信息
Search
Submit
Cancel
Nanjing RegeneCore Biotech Co.,Ltd
Nanjing RegeneCore Biotech Co.,Ltd

REGENECORE is an innovati₽✔÷≠ve start-up company und→÷¥er the YOUNGY Group, advocating science and cul‌¶ture, paying attention to the growth of employeesα∞☆ and enterprises, and maintaining h↑®uman health.

Nanjing RegeneCore Biotech Co.,Lt♦₽d
Nanjing RegeneCore Biotech Co.±↑♦,Ltd

Mature and complete nanobody humanization tec™↓hnology platform, antibody immunogenicity deteλ☆¥ction technology platform, and high-through®"₹↔put nanobody screening technology platf₹¶orm.

這(zhè)是(shì)描述信息

Nanjing RegeneCore Biotech Co.,Ltd

Nanjing RegeneCore Biotech♦∑ Co.,Ltd is established in the Biomedi¶δλcal Valley of National Nanjing Jiangbe‍↓↑i New Area, with a research and office base o₹₹f nearly 4000 square meters. It i♠>s one of the first research and deve£>÷αlopment institutions in the field of nanobodiesλ©δ​ in China. The compa♠λ§ny's international scientific ‌∏" consulting expert team has rich experienc≤±™γe in the research and development of cell theraε↔•py products and clinical applications, p ∏roviding strong guaranteeΩ'σs for the precise positioning₹×‌ and success rate of resear ®•ch and development products. The compan≈÷↑y has mature and leading nan​ε♥Ωobody screening technology, an←<✘↑d conducts in-depth development in mu¶≠×ltiple application fields based on ★ this technology.

more
company

NEWS

Nanjing Rongjiekang RC1416 dual antibody has obtained 2 clinical trial licenses again

Nanjing Rongjiekang RC14÷∏<β16 dual antibody has obta∞‌  ined 2 clinical trial ♥πlicenses again

Recently, Nanjing RegeneCore Biotechnology ₽←♦Co., Ltd.'s RC1416 project has consecuti↕ ♣​vely obtained Investigational New Dr♠✔™ug (IND) approvals from the National Medical P¶>₩∑roducts Administration's Centλ>​☆er for Drug Evaluation (CDE)₩​® for indications of atopic dermatitis (A↓γ‍D) and chronic obstructi≤★ve pulmonary disease (COPD). The expansion of☆‌™¥ these indications has further ‌ diversified the clinical application scenar§ ®αios of RC1416 injection, providing better tr₽<₹σeatment options for more patients..
融捷集團:競逐新賽道(dào),勇攀生(shēng)命科(kē)技(jì)高(gāo)峰

融捷集團:競逐新賽道(dào),勇攀生(shēng)命科(kē)技£ ₩←(jì)高(gāo)峰

近(jìn)日(rì),南京博爾迪生物科技有限公≠γ≥司發布的(de)一(yī)則招募中重度哮喘患者的(de)消息引人(rén)關注。原來(☆☆∏lái),由融捷康自(zì)研的(de)國(guó)©÷內(nèi)首個(gè)自(zì)免雙特異性納米抗體(tǐ)₹≥<藥物(wù)——RC1416注射液,正在全國(guó)數(shù)十←≈家(jiā)知(zhī)名醫(yī)院開(kāi)展臨床研究。這(zh ♠è)款雙抗藥品在藥效、安全性和(hé)成藥性等多(duō)重指标上(shàng)具有(yǒ♦™↕u)較好(hǎo)的(de)優勢,未來(lái)有(yǒu)望成為(wèi↓ ↓)中重度哮喘患者的(de)福音(yīn)。
Recruitment of Patients with Moderate to Severe Asthma

Recruitment of Patients with Moderate to Severe<≈ Asthma

RC1416 injection, develo÷≥'ped by Nanjing RegeneCore ↕£§÷Biotech Co.,Ltd, is currently underg♥γoing a Phase Ib clinical stud↓∞☆×y to "evaluate the safety, tolerabil≠σ™ity, pharmacokinetics, pharmacodynamics, immun♣©¶•ogenicity, and prelimi££nary effectiveness of RC1416 injection in ε§&patients with moderate to severe ׶asthma." The lead inst↔γitution for this study is t↓÷he China-Japan Friendship Hospital in←>♥β Beijing, and it is simultaneously being conduct"βed at dozens of renowned hos‍÷♥→pitals across the country.

 

Platforms

High throughput nanobody screening technol ¶$βogy platform, nanobody humanization technol•αogy platform, antiboα≤"dy immunogenicity detection technology plaε↕σtform, biomacromolecule analysis technology γ<÷✔platform, antibody drug CMC process de"£velopment technology platform

TEL:

025-58608860

Address: Room 07 Building 16 Treeh"βδ&ouse, No. 73, Tanmi Road, Ji$ ¥✔angbei New District, Nanjing

Enterprise email:rjk@regenecore.com

 

這(zhè)是(shì)描述信息

WeChat cooperative consultation

You are the th visitor

午夜A片麻豆精东传媒_国产午夜精品一区二区三区四区_八戒午夜福利理论片_午夜福利电影_午夜成人性做爰A片无码潘金莲_午夜家庭影院_久久午夜无码鲁丝片午夜精品_午夜福利三级理论电影_国产午夜精品一区二区_潘金莲裸体午夜理伦A片_婷婷涩嫩草鲁丝久久午夜精品_午夜视频